Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
Positive momentum driven by analyst upgrades and strong commercial execution of Amtagvi, with upcoming Q4 clinical data serving as a key long-term catalyst.
Goldman Sachs reinstated coverage of Iovance with a Buy rating and a $15 price target on September 24, 2026. The firm cited improving operational efficiencies and gross margins for the company's lead product, Amtagvi, as key drivers for future growth.
GurufocusIovance reported the grant of 179,750 stock options to new non-executive employees on September 18, 2026. While routine, such filings are monitored for dilution impact and corporate growth signals.
BioSpace